Cumberland Pharma gets FDA Fast Track for ifetroban in DMD heart disease

CUMBERLAND PHARMACEUTICALS INC

FDA Fast Track Designation granted for ifetroban targeting fatal heart disease in Duchenne muscular dystrophy.
Designation follows previous Orphan Drug and Rare Pediatric Disease Designations for same indication.
Phase 2 FIGHT DMD trial showed 5.4% improvement in left ventricular ejection fraction over 12 months.
Fast Track enables expedited review, rolling submission, and more frequent FDA interactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.